نتایج جستجو برای: teriflunomide
تعداد نتایج: 247 فیلتر نتایج به سال:
BACKGROUND The advent of oral disease-modifying therapies fundamentally changed the treatment of multiple sclerosis. Nevertheless, impressions of their relative efficacy and tolerability are primarily founded on expert opinion. OBJECTIVE The purpose of this study was to determine whether oral disease-modifying therapies were better tolerated and/or more effective for controlling multiple scle...
Reduction in nucleotide pools through the inhibition of mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) has been demonstrated to effectively reduce cancer cell proliferation and tumour growth. The current study sought to investigate whether this antiproliferative effect could be enhanced by combining Chk1 kinase inhibition. The pharmacological activity of DHODH inhibitor teriflunomide...
Background: Teriflunomide is a first-line oral immunomodulatory agent approved in China for the treatment of relapsing multiple sclerosis. Objective: To compare outcomes teriflunomide and no disease-modifying therapy (DMT) (in first year) multi-center real-world Chinese sclerosis patients. Design: Retrospective study. Methods: This study was conducted five tertiary hospitals different geographi...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید